Study S002052

Effect of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Subclinical Atherosclerosis in Non-diabetic Patients With Psoriatic Arthritis - a Proof-of-concept Randomized Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07251556
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 40
Start: 2025-12-01
Primary completion: 2027-01-01
Lead sponsor: Chinese University of Hong Kong
Conditions: Psoriasis Arthritis
Interventions: DRUG:Semaglutide 0.5 mg; DRUG:Semaglutide 1.0 mg; DRUG:Semaglutide 0.25 mg; OTHER:No intervention
Results posted: FALSE

Registered primary outcomes

Difference in the proportion of subjects with CIMT between the semaglutide group and control group over a period of 24 weeks. [24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.